tuberculosi
also
repres
substanti
challeng
global
health
account
allcaus
dali
lost
worldwid
estim
million
death
target
global
tb
plan
reduc
tuberculosi
death
half
record
thought
europ
africa
fail
meet
goal
control
effort
hamper
limit
vaccin
effect
coinfect
hiv
insuffici
diagnost
capac
low
incom
set
prolong
treatment
cours
emerg
drug
resist
strain
global
estim
death
annual
attribut
influenza
viral
reassort
lead
novel
strain
pandem
potenti
strain
emerg
mexico
rapidli
spread
worldwid
strain
remain
domin
influenza
strain
across
europ
emerg
strain
provid
caus
immedi
concern
sever
acut
respiratori
syndrom
sar
aros
china
rapidli
caus
case
case
fatal
almost
emerg
middl
east
respiratori
syndrom
coronaviru
caus
global
concern
respiratori
syncyti
viru
rsv
estim
caus
year
million
new
episod
rsvassoci
acut
lower
respiratori
tract
infect
worldwid
children
younger
five
year
estim
death
per
year
almost
lowincom
set
variabl
coverag
mmr
measl
mump
rubella
vaccin
well
document
measl
still
respons
consider
diseas
burden
global
million
dali
amongst
infect
owe
sever
notabl
outbreak
pertussi
receiv
media
coverag
highincom
countri
respiratori
infect
implic
aetiolog
chronic
respiratori
diseas
asthma
chronic
obstruct
pulmonari
disord
cystic
fibrosi
well
act
trigger
acut
cardiovascular
event
uk
institut
receiv
estim
billion
public
charit
fund
carri
infecti
diseas
research
around
onethird
design
relat
global
health
accord
estim
polici
cure
uk
rank
second
global
term
amount
r
fund
infecti
diseas
research
fund
cover
type
scienc
along
r
valu
chain
preclin
oper
implement
research
report
fund
respiratori
infectionrel
research
award
uk
institut
identifi
area
research
strength
possibl
invest
gap
relat
respiratori
global
health
relev
policymak
funder
research
briefli
discuss
new
approach
might
help
alloc
exist
resourc
identifi
new
sourc
invest
analys
studi
fund
period
inclus
identifi
relev
respiratori
infecti
diseas
global
health
studi
defin
investig
diseas
endem
uk
studi
clear
refer
anoth
countri
eg
tuberculosi
south
africa
pneumonia
categori
includ
preclin
studi
exclud
openaccess
data
pharmaceut
industri
limit
repres
method
describ
detail
previous
overarch
dataset
construct
studi
screen
relev
infecti
diseas
research
assign
mani
primari
diseas
categori
appropri
within
categori
topicspecif
subsect
includ
specif
pathogen
diseas
document
studi
also
alloc
one
four
categori
along
r
valu
chain
preclin
phase
product
develop
implement
oper
research
funder
either
consid
right
group
categori
inhous
univers
fund
research
chariti
govern
depart
total
funder
categori
use
categoris
carri
author
mgh
provision
dataset
circul
author
review
comment
jrf
mkc
fbw
verifi
random
sampl
dataset
author
agreement
measur
kappa
score
differ
settl
consensu
exclud
studi
immedi
relev
infect
veterinari
infecti
diseas
research
studi
unless
clear
zoonot
compon
studi
uk
collabor
fund
award
nonuk
institut
unfund
studi
also
exclud
grant
award
currenc
pound
sterl
convert
uk
pound
use
mean
exchang
rate
year
award
award
adjust
inflat
report
uk
pound
use
fold
differ
statist
test
nonparametr
mannwhitney
rank
sum
test
ksampl
test
nonparametr
wilcoxon
signedrank
test
compar
total
invest
number
studi
mean
grant
median
grant
accord
specif
infect
diseas
system
fund
organis
crosscut
categori
associ
diseas
burden
research
invest
assess
use
spearman
rank
correl
coeffici
rho
valu
greater
equal
consid
strongli
correl
greater
equal
less
consid
moder
correl
valu
equal
consid
poorli
total
studi
screen
identifi
studi
met
inclus
criteria
total
invest
f
r
p
e
e
r
r
e
v
e
w
n
l
translat
r
invest
focu
influenza
also
undoubtedli
least
part
due
highlight
emerg
strain
pandem
potenti
strong
correl
burden
invest
encourag
broadli
highburden
diseas
receiv
greater
fund
pneumonia
key
except
lowerburden
infect
less
fund
within
therapeut
research
proportionatelygreat
invest
tuberculosi
compar
influenza
seem
appropri
tuberculosisrel
focu
within
diagnost
new
highimpact
infect
threat
human
often
respiratori
natur
sar
influenza
middl
east
respiratori
syndrom
potenti
highli
virul
rapid
transmiss
global
spread
substanti
health
econom
impact
although
difficult
accur
quantifi
dataset
littl
fund
research
develop
predict
epidemiolog
model
futur
pandem
would
import
part
infect
prevent
control
howev
caution
must
exercis
develop
epidemiolog
limit
fund
pneumococc
pneumonia
research
whilst
infect
mening
may
declin
countri
due
success
introduct
new
vaccin
still
mani
area
global
weak
health
system
pneumococc
incid
high
also
evid
respiratori
infect
transmiss
mass
gather
hajj
addit
provid
meningococc
influenza
vaccin
travel
invest
oper
research
explor
health
system
respons
emerg
threat
effici
way
provid
prevent
medicin
well
measur
effect
prevent
therapi
littl
fund
translat
research
relat
pneumonia
clear
gap
uk
portfolio
vaccineprevent
diseas
measl
pertussi
caus
high
diseas
burden
global
also
receiv
limit
research
fund
despit
clearli
need
translat
oper
research
worldwid
burden
drugresist
tuberculosi
rapidli
increas
estim
case
multidrugresist
tuberculosi
worldwid
great
variat
countri
emerg
last
decad
extens
drugresist
case
given
difficulti
develop
effect
vaccin
need
new
diagnost
therapeut
target
use
exist
medicin
becom
even
import
report
resist
antivir
drug
use
treat
influenza
emphasis
need
develop
effect
antivir
effect
vaccin
pauciti
research
antimicrobi
resist
concern
highlight
uk
chief
medic
offic
new
fund
research
relat
antimicrobi
resist
provid
believ
funder
follow
lead
countri
underinvest
tuberculosi
r
studi
sever
limit
highlight
discuss
detail
elsewher
littl
publiclyavail
data
pharmaceut
industri
henc
data
gap
relat
fund
clinic
trial
develop
vaccin
diagnost
pharmaceut
biotechnolog
industri
financ
beyond
diseas
burden
measur
econom
burden
also
utilis
prioritis
limit
resourc
littl
inform
avail
regard
econom
impact
respiratori
infect
reli
origin
data
complet
accur
unabl
take
account
distribut
fund
lead
institut
collabor
partner
assess
quantiti
award
given
overhead
impact
introduct
fulleconom
cost
also
assign
studi
categori
subject
imperfect
process
although
use
two
research
reduc
interobserv
error
studi
focus
ukl
invest
know
similar
pattern
eg
domin
preclin
research
lack
public
charitablyfund
clinic
requir
studi
unfund
fund
uk
predominantli
fund
preclin
scienc
tuberculosi
studi
respiratori
diseas
high
global
burden
pneumoniarel
diseas
warrant
greater
invest
histor
receiv
prioriti
area
includ
antimicrobi
resist
particularli
within
tuberculosi
econom
proactiv
invest
emerg
infecti
threat
first
studi
analys
public
philanthrop
invest
award
uk
institut
respiratori
infecti
diseas
research
identifi
area
underinvest
result
highlight
clear
gap
uk
research
portfolio
illustr
prioriti
area
funder
policymak
also
highlight
strength
preclin
research
uk
privat
sector
data
contribut
area
diagnost
vaccin
develop
current
unknown
intern
data
requir
assess
true
research
gap
relat
global
respiratori
infecti
diseas
invest
categoris
subject
take
account
fund
overhead
impact
introduct
full
econom
cost
global
estim
death
annual
attribut
influenza
limit
fund
pneumococc
pneumonia
research
whilst
infect
mening
may
declin
countri
due
success
introduct
new
vaccin
still
mani
area
global
weak
health
system
pneumococc
incid
high
also
evid
respiratori
infect
transmiss
mass
gather
hajj
addit
provid
meningococc
influenza
vaccin
travel
invest
oper
research
explor
health
system
respons
emerg
threat
effici
way
provid
prevent
medicin
well
measur
effect
prevent
therapi
littl
fund
translat
research
relat
pneumonia
clear
gap
uk
portfolio
vaccineprevent
diseas
measl
pertussi
caus
high
diseas
burden
global
also
receiv
limit
research
fund
despit
clearli
need
translat
oper
research
worldwid
burden
drugresist
tuberculosi
rapidli
increas
estim
case
multidrugresist
tuberculosi
worldwid
great
variat
countri
emerg
last
decad
extens
drugresist
case
given
difficulti
develop
effect
vaccin
need
new
diagnost
therapeut
target
use
exist
medicin
becom
even
import
report
resist
antivir
drug
use
treat
influenza
emphasis
need
develop
effect
antivir
effect
vaccin
pauciti
research
antimicrobi
resist
concern
highlight
uk
chief
medic
offic
new
fund
research
relat
antimicrobi
resist
provid
believ
funder
follow
lead
countri
underinvest
tuberculosi
r
studi
sever
limit
highlight
discuss
detail
elsewher
littl
publiclyavail
data
pharmaceut
industri
henc
data
gap
relat
fund
clinic
trial
develop
vaccin
diagnost
pharmaceut
biotechnolog
industri
financ
beyond
diseas
burden
measur
econom
burden
also
utilis
prioritis
limit
resourc
littl
inform
avail
regard
econom
impact
respiratori
infect
reli
origin
data
complet
accur
unabl
take
account
distribut
fund
lead
institut
collabor
partner
assess
quantiti
award
given
overhead
impact
introduct
fulleconom
cost
also
assign
studi
categori
subject
imperfect
process
although
use
two
research
uk
predominantli
fund
preclin
scienc
tuberculosi
studi
respiratori
diseas
high
global
burden
pneumoniarel
diseas
warrant
greater
invest
histor
receiv
prioriti
area
includ
antimicrobi
resist
econom
proactiv
invest
emerg
infecti
threat
first
studi
analys
public
philanthrop
invest
award
uk
institut
respiratori
infecti
diseas
research
identifi
area
underinvest
result
highlight
clear
gap
uk
research
portfolio
illustr
prioriti
area
funder
policymak
also
highlight
strength
preclin
research
uk
privat
sector
data
contribut
area
diagnost
vaccin
develop
current
unknown
intern
data
requir
assess
true
research
gap
relat
global
respiratori
infecti
diseas
invest
categoris
subject
take
account
fund
overhead
impact
introduct
full
econom
cost
tuberculosi
also
repres
substanti
challeng
global
health
account
allcaus
dali
lost
worldwid
estim
million
death
target
global
tb
plan
reduc
tuberculosi
death
half
record
thought
europ
africa
fail
meet
goal
control
effort
hamper
limit
vaccin
effect
coinfect
hiv
insuffici
diagnost
capac
low
incom
set
prolong
treatment
cours
emerg
drug
resist
strain
global
estim
death
annual
attribut
influenza
f
r
p
e
e
r
r
e
v
e
w
n
l
aetiolog
chronic
respiratori
diseas
asthma
chronic
obstruct
pulmonari
disord
cystic
fibrosi
well
act
trigger
acut
cardiovascular
event
uk
institut
receiv
estim
billion
public
charit
fund
carri
infecti
diseas
research
around
onethird
design
relat
global
health
accord
estim
polici
cure
uk
rank
second
global
term
amount
r
fund
infecti
diseas
research
fund
cover
type
scienc
along
r
valu
chain
preclin
oper
implement
research
report
fund
respiratori
infectionrel
research
award
uk
institut
identifi
area
research
strength
possibl
invest
gap
relat
respiratori
global
health
relev
policymak
funder
research
briefli
discuss
new
approach
might
help
alloc
exist
resourc
identifi
new
sourc
invest
analys
studi
fund
period
inclus
identifi
relev
respiratori
infecti
diseas
global
health
studi
defin
investig
diseas
endem
uk
studi
clear
refer
anoth
countri
eg
tuberculosi
south
africa
pneumonia
categori
includ
preclin
studi
exclud
openaccess
data
pharmaceut
industri
limit
repres
method
describ
detail
previous
overarch
dataset
construct
studi
screen
relev
infecti
diseas
research
assign
mani
primari
diseas
categori
appropri
within
categori
topicspecif
subsect
includ
specif
pathogen
diseas
document
studi
also
alloc
one
four
categori
along
r
valu
chain
preclin
phase
product
develop
implement
oper
research
funder
either
consid
right
group
categori
inhous
univers
fund
research
chariti
govern
depart
total
funder
categori
use
categoris
limit
fund
pneumococc
pneumonia
research
whilst
infect
mening
may
declin
countri
due
success
introduct
new
vaccin
still
mani
area
global
weak
health
system
pneumococc
incid
high
also
evid
respiratori
infect
transmiss
mass
gather
hajj
addit
provid
meningococc
influenza
vaccin
travel
invest
oper
research
explor
health
system
respons
emerg
threat
effici
way
provid
prevent
medicin
well
measur
effect
prevent
therapi
littl
fund
translat
research
relat
pneumonia
clear
gap
uk
portfolio
vaccineprevent
diseas
measl
pertussi
caus
high
diseas
burden
global
also
receiv
limit
research
fund
despit
clearli
need
translat
oper
research
worldwid
burden
drugresist
tuberculosi
rapidli
increas
estim
case
multidrugresist
tuberculosi
worldwid
great
variat
countri
emerg
last
decad
extens
drugresist
case
given
difficulti
develop
effect
vaccin
need
new
diagnost
therapeut
target
use
exist
medicin
becom
even
import
report
resist
antivir
drug
use
pauciti
research
antimicrobi
resist
concern
highlight
uk
chief
medic
offic
new
fund
research
relat
antimicrobi
resist
provid
believ
funder
follow
lead
countri
underinvest
tuberculosi
r
also
note
consider
incid
ultim
influenc
alloc
resourc
consider
may
includ
preval
predict
impact
diseas
treatabl
diseas
antibiot
cours
combin
differ
pneumonia
tuberculosi
cofactor
comorb
eg
studi
sever
limit
highlight
discuss
detail
elsewher
littl
publiclyavail
data
pharmaceut
industri
henc
data
gap
relat
fund
clinic
trial
develop
vaccin
diagnost
f
r
p
e
e
r
r
e
v
e
w
n
l
